Transfusion Medicine and Hemotherapy最新文献

{"title":"Patient Plasma Management.","authors":"Thomas Thiele","doi":"10.1159/000544922","DOIUrl":"https://doi.org/10.1159/000544922","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 2","pages":"111-113"},"PeriodicalIF":1.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Attack!\" Cellular Therapies to Attack Pathogens and Tumors.","authors":"Britta Eiz-Vesper, Halvard Bonig","doi":"10.1159/000543415","DOIUrl":"10.1159/000543415","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"1-4"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Selected Crystalloid and Colloid Solutions on Coagulation Status Evaluated by Rotational Thromboelastometry and Platelet Function Analyser: An in vitro Study.","authors":"Jakub Jonas, Miroslav Durila, Tomas Vymazal","doi":"10.1159/000541772","DOIUrl":"https://doi.org/10.1159/000541772","url":null,"abstract":"<p><strong>Introduction: </strong>Crystalloid and colloid solutions commonly used in intensive and perioperative care can affect haemocoagulation status. This in vitro study assessed the impact of Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions on primary and secondary haemostasis using rotational thromboelastometry and platelet function analyser.</p><p><strong>Methods: </strong>In this prospective study, we examined blood samples from 20 healthy volunteers using rotational thromboelastometry and platelet function analyser. Simultaneously, we analysed the blood samples subjected to 10% dilution using Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions.</p><p><strong>Results: </strong>Compared to controls, Plasma-Lyte shortened EXTEM-CT (<i>p</i> = 0.005) and reduced FIBTEM-MCF (<i>p</i> = 0.017). albunorm 5% prolonged EXTEM-CFT (<i>p</i> = 0.001), decreased EXTEM-alpha (<i>p</i> < 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (<i>p</i> < 0.001, <i>p</i> = 0.038, <i>p</i> = 0.001, respectively), along with MCE in the PLTEM test (<i>p</i> < 0.001). Gelaspan 4% also prolonged EXTEM-CFT (<i>p</i> < 0.001), decreased EXTEM-alpha (<i>p</i> < 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (<i>p</i> < 0.001, <i>p</i> < 0.001, <i>p</i> = 0.009, respectively), along with MCE in the PLTEM test (<i>p</i> < 0.001). Gelaspan 4% also reduced EXTEM-CT (<i>p</i> = 0.021). All solution prolonged CT in PFA Col/ADP (<i>p</i> = 0.003 for Plasma-Lyte, <i>p</i> < 0.001 for albunorm and Gelaspan) and albunorm 5% also prolonged CT in Col/Epi (<i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>Plasma-Lyte had the least effect on secondary haemostasis, whereas albunorm 5% had the least effect among colloids. Gelaspan 4% adversely affected the propagation phase of coagulation, maximal strength and elasticity of the coagulum, and the level of functional fibrinogen. All solutions adversely affected platelet function in primary haemostasis, with Plasma-Lyte showing the least effect.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 2","pages":"132-141"},"PeriodicalIF":1.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion Risk in Open, Laparoscopic, and Robotic-Assisted Surgery: A Propensity Score Matched Case-Control Study across Surgical Disciplines.","authors":"Florian Rumpf, Suma Choorapoikayil, Lotta Hof, Keyan Salari, Olaf Baumhove, Alexandra Bayer, Patrick Friederich, Jens Friedrich, Gunnar Elke, Matthias Gruenewald, Diana Narita, Ansgar Raadts, Klaus Schwendner, Dana J Jenke, Andrea U Steinbicker, Josef Thoma, Viola Weber, Markus Velten, Maria Wittmann, Henry Weigt, Björn Lange, Kai Zacharowski, Patrick Meybohm","doi":"10.1159/000540981","DOIUrl":"https://doi.org/10.1159/000540981","url":null,"abstract":"<p><strong>Introduction: </strong>Robotic-assisted surgery is increasingly performed in various surgical disciplines demonstrating improved oncological and functional outcomes compared to conventional surgery.</p><p><strong>Objective: </strong>Unclear is how robotic-assisted surgery affects perioperative anemia and the need for blood products.</p><p><strong>Methods: </strong>In this case-control study, 15,009 matched patient pairs undergoing urological, visceral, or thoracic surgery were included. Pairwise comparisons between robotic-assisted surgery, laparoscopic surgery, and open surgery were performed with propensity score matching.</p><p><strong>Results: </strong>Robotic-assisted surgery compared to open surgery was associated with a risk reduction of allogeneic red blood cell transfusion by RR: 0.32 (95% CI: 0.27-0.37) and a limited reduction of perioperative hemoglobin (perioperative hemoglobin difference of 0.40 g/dL, 95% CI: 0.31-0.49). Robotic-assisted surgery was associated with a shorter length of hospital stay by 4.29 days (95% CI: 3.74-4.84). Compared to laparoscopic surgery, robotic-assisted surgery had no significant effect on red blood cell transfusions (RR: 0.94, 95% CI: 0.75-1.18), perioperative hemoglobin (0.27 g/dL, 95% CI: 0.16-0.38), or length of hospital stay 0.53 days (95% CI: -0.14-1.19).</p><p><strong>Conclusions: </strong>Robotic-assisted and laparoscopic procedures are associated with reduced blood transfusions compared to open surgery and, thus the advancement of minimally invasive procedures constitutes an important measure to improve patient outcomes.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 2","pages":"142-151"},"PeriodicalIF":1.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.","authors":"Fenja Gierschek, Juliane Schlueter, Ines Kühnel, Frederik Fabian Feigl, Dominik Schmiedel, Maren Prüfer, Leon Buchinger, Adelheid Cerwenka, Claudia Cappel, Sabine Huenecke, Ulrike Köhl, Winfried S Wels, Evelyn Ullrich","doi":"10.1159/000540962","DOIUrl":"10.1159/000540962","url":null,"abstract":"<p><strong>Background: </strong>Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML.</p><p><strong>Summary: </strong>Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC).</p><p><strong>Key messages: </strong>In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"42-60"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.","authors":"Kiriakos Koukoulias, Penelope Georgia Papayanni, Ann Marie Leen, Spyridoula Vasileiou","doi":"10.1159/000540961","DOIUrl":"10.1159/000540961","url":null,"abstract":"<p><strong>Background: </strong>Immunocompromised individuals are at major risk for severe infectious complications. This is particularly relevant in the context of allogeneic hematopoietic stem cell transplantation (allo-HCT) - a treatment modality that has proven curative for a range of malignant and nonmalignant hematological diseases. However, transplant-associated immune suppression leaves patients susceptible to infectious complications from viruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and BK virus (BKV). While pharmacological agents are available to prevent and/or treat some of these viruses, they can be associated with significant toxicities and are often ineffective. To circumvent these issues, several groups have explored the clinical potential of adoptively transferred virus-specific T cells (VSTs) to prevent/treat virus-associated complications after allo-HCT or solid organ transplantation (SOT) and this review will provide an overview of these endeavors.</p><p><strong>Summary: </strong>This review will focus on the progress that has been made over the past 30 years in the field of nonengineered VST manufacturing technologies and will summarize the clinical experience with VSTs, primarily in the posttransplant setting.</p><p><strong>Key messages: </strong>Over the last 3 decades, adoptively transferred VSTs - both HCT donor and third party-derived - have been tested in numerous single and multicenter clinical trials and have unequivocally proven to be safe and associated with clinical activity.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"5-26"},"PeriodicalIF":1.9,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Eva Rettinger","doi":"10.1159/000540964","DOIUrl":"10.1159/000540964","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapies in general, and cellular immunotherapies, in particular are becoming increasingly integrated into current personalized cancer treatment, though still facing some obstacles in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.</p><p><strong>Summary: </strong>The concept of isolating immune effector cells, expanding their numbers, enhancing their anticancer capabilities by modifying them without increasing their alloreactive potential is the mainstay of adoptive cellular immunotherapy after allogeneic HSCT. In this context, cytokine-induced killer (CIK) cells, a polyfunctional heterogenous population of conventional T cells, natural killer (NK) cells, and T-NK cells capable of using T cell and NK cell-like cytotoxicity mechanisms against a various cancers, showed minimal alloreactivity in pediatric and adult patients allografted for hematological malignancies. Furthermore, CIK cells have already shown compatibility with chemotherapy, different kinds of immune checkpoint inhibitors, epigenetic drugs, antibody-targeted therapies, and recently with chimeric antigen receptor-engineering techniques.</p><p><strong>Key messages: </strong>Hence, CIK cell therapy represents a unique platform for adoptive cell immunotherapies, guiding innovative treatment approaches from preclinical research to future clinical trials for cancer patients with yet unmet medical needs. In this context, the allogeneic HSCT setting provides an alternative source for safe and efficient adoptive allogeneic CIK cell strategies against a variety of cancers.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"77-95"},"PeriodicalIF":1.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000541144","DOIUrl":"https://doi.org/10.1159/000541144","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000502158.].</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 5","pages":"361"},"PeriodicalIF":1.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.","authors":"Wilma Barcellini, Bruno Fattizzo","doi":"10.1159/000540475","DOIUrl":"10.1159/000540475","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune hemolytic anemia (AIHA) is a rare disease due to increased destruction of erythrocytes by autoantibodies, with or without complement activation.</p><p><strong>Summary: </strong>AIHA is usually classified in warm AIHA (wAIHA) and cold agglutinin disease (CAD), based on isotype and thermal amplitude of the autoantibody. The direct antiglobulin test (DAT) or Coombs test is the cornerstone of AIHA diagnosis, as it is positive with anti-IgG in wAIHA, and with anti-C3d/IgM antisera plus high titer cold agglutinins in CAD. Therapy is quite different, as steroids and rituximab are effective in the former, but have a lower response rate and duration in the latter. Splenectomy, which is still a good option for young/fit wAIHA, is contraindicated in CAD, and classic immunosuppressants are moving to further lines. Several new drugs are increasingly used or are in trials for relapsed/refractory AIHAs, including B-cell (parsaclisib, ibrutinib, rilzabrutinib), and plasma cell target therapies (bortezomib, daratumumab), bispecific agents (ianalumab, obexelimab, povetacicept), neonatal Fc receptor blockers (nipocalimab), and complement inhibitors (sutimlimab, riliprubart, pegcetacoplan, iptacopan). Clinically, AIHAs are highly heterogeneous, from mild/compensated to life-threatening/fulminant, and may be primary or associated with infections, neoplasms, autoimmune diseases, transplants, immunodeficiencies, and drugs. Along with all these variables, there are rare forms like mixed (wAIHA plus CAD), atypical (IgA or warm IgM driven), and DAT negative, where the diagnosis and clinical management are particularly challenging.</p><p><strong>Key messages: </strong>This article covers the classic clinical features, diagnosis, and therapy of wAIHA and CAD, and focuses, with the support of clinical vignettes, on difficult diagnosis and refractory/relapsing cases requiring novel therapies.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 5","pages":"321-331"},"PeriodicalIF":1.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.","authors":"Pieter L Lindenbergh, Sjoukje J C van der Stegen","doi":"10.1159/000540473","DOIUrl":"10.1159/000540473","url":null,"abstract":"<p><strong>Background: </strong>The clinical success of autologous adoptive cell therapy (ACT) is substantial but wide application is challenged by the quality and quantity of the patient's immune cells and the need for personalized manufacturing processes. Induced pluripotent stem cells (iPSCs) can be differentiated into immune effectors and thus provide an alternative, allogeneic cell source for ACT. Here, we compare iPSC-derived immune effectors to their PBMC-derived counterparts and review iPSC-derived ACT products currently under preclinical and clinical development.</p><p><strong>Summary: </strong>iPSC-derived T cells, NK cells, macrophages, and neutrophils largely mimic their PBMC-derived counterparts in terms of cell-surface marker expression and cytotoxic effector functions. iPSC-derived immune effectors can be engineered with chimeric antigen receptors and other activating receptors to redirect their cytotoxic potential specifically to tumor-associated antigens (TAAs). However, several differences between iPSC- and PBMC-derived immune effectors remain and have inspired additional engineering strategies to enhance the antitumor capacity of iPSC-derived immune effectors.</p><p><strong>Key messages: </strong>iPSCs can be engineered to facilitate the generation of immune effectors with homogenous specificity for TAAs and enhanced effector functions. TAA-specific and functionally enhanced iPSC-derived T and NK cells are currently undergoing clinical evaluation in phase 1 trials. Engineered iPSC-derived macrophages and neutrophils are in preclinical development.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"27-41"},"PeriodicalIF":1.9,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}